Nothing Special   »   [go: up one dir, main page]

AR001790A1 - Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos - Google Patents

Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos

Info

Publication number
AR001790A1
AR001790A1 AR33519696A AR33519696A AR001790A1 AR 001790 A1 AR001790 A1 AR 001790A1 AR 33519696 A AR33519696 A AR 33519696A AR 33519696 A AR33519696 A AR 33519696A AR 001790 A1 AR001790 A1 AR 001790A1
Authority
AR
Argentina
Prior art keywords
modeled
treating
transdermal patch
muscarinic receptor
patch formulations
Prior art date
Application number
AR33519696A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR001790A1 publication Critical patent/AR001790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se trata de formulaciones farmacéuticas bajo la forma de parches o emplastos transdérmicos, que contienen como agente activo, xanomelina defórmula (I), de aplicación para el tratamiento de la enfermedad de Alzheimer, en funciónde su actividad muscarínica.
AR33519696A 1995-01-30 1996-01-26 Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos AR001790A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38047895A 1995-01-30 1995-01-30

Publications (1)

Publication Number Publication Date
AR001790A1 true AR001790A1 (es) 1997-12-10

Family

ID=23501315

Family Applications (1)

Application Number Title Priority Date Filing Date
AR33519696A AR001790A1 (es) 1995-01-30 1996-01-26 Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos

Country Status (23)

Country Link
US (1) US5980933A (es)
EP (1) EP0723781A3 (es)
JP (1) JPH10513181A (es)
KR (1) KR19980701730A (es)
AR (1) AR001790A1 (es)
AU (1) AU709379B2 (es)
BR (1) BR9600216A (es)
CA (1) CA2210711A1 (es)
CO (1) CO4700420A1 (es)
CZ (1) CZ240297A3 (es)
EA (1) EA001083B1 (es)
HU (1) HUP9800832A3 (es)
IL (1) IL116895A (es)
NO (1) NO973471L (es)
NZ (1) NZ301197A (es)
PE (1) PE17397A1 (es)
PL (1) PL321686A1 (es)
RO (1) RO117146B1 (es)
TR (1) TR199700711T1 (es)
TW (1) TW304167B (es)
WO (1) WO1996023463A1 (es)
YU (1) YU5196A (es)
ZA (1) ZA96530B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP5106715B2 (ja) * 1999-09-24 2012-12-26 アルロン・ジャパン株式会社 Ｌ−アスコルビン酸、ｌ−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物
US7691404B2 (en) * 2000-11-06 2010-04-06 Samyang Corporation Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
DE102005050431A1 (de) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US20070259859A1 (en) * 2006-05-04 2007-11-08 De Bruin Natasja M W J Muscarinic agonists to treat impulse control disorders
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US8846740B2 (en) 2011-01-04 2014-09-30 Biological Responsibility, Llc Biotherapeutics for the treatment of infectious diseases
CA2978244A1 (en) 2015-03-06 2016-09-15 Thomas N. Chase Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
ATE76584T1 (de) * 1987-08-28 1992-06-15 Lilly Co Eli Die permeation verbessernde zusammensetzung.
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DE3843239C1 (es) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions

Also Published As

Publication number Publication date
AU709379B2 (en) 1999-08-26
HUP9800832A2 (hu) 1999-01-28
IL116895A (en) 2000-08-31
NO973471D0 (no) 1997-07-28
IL116895A0 (en) 1996-05-14
TW304167B (es) 1997-05-01
YU5196A (sh) 1998-08-14
ZA96530B (en) 1997-07-23
KR19980701730A (ko) 1998-06-25
PE17397A1 (es) 1997-05-21
NO973471L (no) 1997-09-19
EP0723781A2 (en) 1996-07-31
TR199700711T1 (xx) 1998-01-21
JPH10513181A (ja) 1998-12-15
CA2210711A1 (en) 1996-08-08
PL321686A1 (en) 1997-12-22
EP0723781A3 (en) 1996-08-07
RO117146B1 (ro) 2001-11-30
HUP9800832A3 (en) 2000-07-28
EA001083B1 (ru) 2000-10-30
BR9600216A (pt) 1998-01-06
MX9705723A (es) 1997-11-29
US5980933A (en) 1999-11-09
EA199700151A1 (ru) 1997-12-30
AU4656596A (en) 1996-08-21
CO4700420A1 (es) 1998-12-29
NZ301197A (en) 1999-09-29
CZ240297A3 (cs) 1998-04-15
WO1996023463A1 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
UY26130A1 (es) Compuestos para tratar la obesidad
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
BR0110420A (pt) Agonistas muscarìnicos
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
GB0225474D0 (en) Therapeutic agents
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
TR199800258T1 (xx) Yeni opioid peptidler.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
AR023957A1 (es) Pirazol carboxamidas utiles para el tratamiento de la obesidad y otros trastornos.
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DE59906392D1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
BR0012610A (pt) Novo derivado de difenilpiperidina
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
CY1108482T1 (el) Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios

Legal Events

Date Code Title Description
FA Abandonment or withdrawal